Eribulin in HER2 Negative Metastatic BrCa

Based on positive results in heavily pre-treated MBC patients, eribulin is being studied as
first-line or second-line chemotherapy treatment. This is a non-randomized, open label study
with participants enrolled in one of two cohorts: Cohort 1. Hormone receptor
(HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) or Cohort
2: Triple negative breast cancer (TNBC) meaning HR-negative/HER2-negative (HR-/HER2-). HR-
means progesterone receptor-negative (PR-) and estrogen receptor-negative (ER-). Beyond
efficacy as measured primarily by response to treatment, investigators will evaluate safety,
tolerability and quality of life. In particular, it is hypothesized that eribulin may have
lower rates of neuropathy, a common side effect of many of the major chemotherapeutics with
activity in MBC. The investigators will study the effect eribulin has on the nerves through
regular questionnaires that ask about any nerve-related symptoms. The investigators also plan
to send blood samples to explore if gene markers may indicate increased sensitivity to the
nerve effects of eribulin.

Inclusion Criteria:

- Histologically or cytologically proven invasive breast cancer, locally recurrent or
metastatic, with at least one measureable lesion according to RECIST v1.1

- Hormone receptor positive or hormone receptor negative HER2-negative disease

- Up to one prior line of chemotherapy for advanced disease is allowed (discontinued at
least 14 days prior to initiation of protocol therapy)

- Prior bevacizumab in the neo/adjuvant or metastatic setting is acceptable

- No limit on prior lines of endocrine therapy, but must be discontinued at least 7 days
prior to initiation of protocol therapy

- Must have completed any prior radiotherapy at least 2 weeks prior to initiation of
protocol therapy

- Must have recovered from reversible effects of prior therapies to no more than grade 1
toxicity, with the exception of alopecia

- Agree to use adequate contraception for the duration of study participation

Exclusion Criteria:

- Pregnant or breastfeeding

- Prior treatment with eribulin

- Prior malignancy other than carcinoma in situ of the cervix or nonmelanoma skin cancer
unless diagnosed and definitively treated at least 3 years before enrollment in this
study

- Clinically significant cardiovascular impairment

- Active brain metastases or unevaluated neurologic symptoms suggestive of brain
metastases

- Pulmonary dysfunction requiring the use of oxygen

- Prior organ allograft requiring immunosuppression

- HIV positive on combination antiretroviral therapy

- Pre-existing grade 3 or 4 neuropathy

- Hypersensitivity to halichondrin B or halichondrin B chemical derivative

- Uncontrolled intercurrent illness

- Inability to read in English